Cadherin 17 is related to recurrence and poor prognosis of cytokeratin 19-positive hepatocellular carcinoma

Chao Wei Lee, Sey-En Lin, Hsin I. Tsai, Po Jung Su, Chia Hsun Hsieh, Yung Chia Kuo, Chang Mu Sung, Cheng Yu Lin, Chi Neu Tsai, Ming Chin Yu

研究成果: 雜誌貢獻文章

5 引文 (Scopus)

摘要

A previous study demonstrated that cytokeratin 19 (CK19) expression in hepatocellular carcinoma (HCC) is an indicator of HCC invasiveness, including lymph node metastasis (LNM), tumor infiltration/non‑encapsulation and poor prognosis. The exact mechanism by which CK19 expression results in poor prognosis remains unclear. Through the use of an Affymetrix U133A oligonucleotide microarray [20 patients with hepatitis B virus (HBV)-HCC], it was demonstrated that cadherin 17 (CDH17) significantly correlated with CK19 expression (R2, 0.867; P10% and CDH17 expression were independent prognostic factors for disease free survival (P=0.010 and 0.002, respectively). In vitro studies showed that epidermal growth factor can induce the expression of both CK19 and CDH17, and CDH17 in turn can enhance the expression of CK19 in HCC. In summary, this study demonstrated that the early recurrence and poor prognosis of CK19(+) HCC may be due to the expression of CDH17, a gene known to be associated with vascular invasion, tumor metastasis, and advanced tumor stage of HCC. Thus, novel therapeutics by targeting CDH17 may be beneficial for CK19(+) HCC.

原文英語
頁(從 - 到)559-567
頁數9
期刊Oncology Letters
15
發行號1
DOIs
出版狀態已發佈 - 一月 1 2018

指紋

Keratin-19
Cadherins
Hepatocellular Carcinoma
Recurrence
Neoplasm Metastasis
Neoplasms
Oligonucleotide Array Sequence Analysis
Epidermal Growth Factor
Hepatitis B virus
Disease-Free Survival
Blood Vessels
Lymph Nodes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

引用此文

Cadherin 17 is related to recurrence and poor prognosis of cytokeratin 19-positive hepatocellular carcinoma. / Lee, Chao Wei; Lin, Sey-En; Tsai, Hsin I.; Su, Po Jung; Hsieh, Chia Hsun; Kuo, Yung Chia; Sung, Chang Mu; Lin, Cheng Yu; Tsai, Chi Neu; Yu, Ming Chin.

於: Oncology Letters, 卷 15, 編號 1, 01.01.2018, p. 559-567.

研究成果: 雜誌貢獻文章

Lee, CW, Lin, S-E, Tsai, HI, Su, PJ, Hsieh, CH, Kuo, YC, Sung, CM, Lin, CY, Tsai, CN & Yu, MC 2018, 'Cadherin 17 is related to recurrence and poor prognosis of cytokeratin 19-positive hepatocellular carcinoma', Oncology Letters, 卷 15, 編號 1, 頁 559-567. https://doi.org/10.3892/ol.2017.7320
Lee, Chao Wei ; Lin, Sey-En ; Tsai, Hsin I. ; Su, Po Jung ; Hsieh, Chia Hsun ; Kuo, Yung Chia ; Sung, Chang Mu ; Lin, Cheng Yu ; Tsai, Chi Neu ; Yu, Ming Chin. / Cadherin 17 is related to recurrence and poor prognosis of cytokeratin 19-positive hepatocellular carcinoma. 於: Oncology Letters. 2018 ; 卷 15, 編號 1. 頁 559-567.
@article{6a16bf86b5584b9e9d09b9675545bb79,
title = "Cadherin 17 is related to recurrence and poor prognosis of cytokeratin 19-positive hepatocellular carcinoma",
abstract = "A previous study demonstrated that cytokeratin 19 (CK19) expression in hepatocellular carcinoma (HCC) is an indicator of HCC invasiveness, including lymph node metastasis (LNM), tumor infiltration/non‑encapsulation and poor prognosis. The exact mechanism by which CK19 expression results in poor prognosis remains unclear. Through the use of an Affymetrix U133A oligonucleotide microarray [20 patients with hepatitis B virus (HBV)-HCC], it was demonstrated that cadherin 17 (CDH17) significantly correlated with CK19 expression (R2, 0.867; P10{\%} and CDH17 expression were independent prognostic factors for disease free survival (P=0.010 and 0.002, respectively). In vitro studies showed that epidermal growth factor can induce the expression of both CK19 and CDH17, and CDH17 in turn can enhance the expression of CK19 in HCC. In summary, this study demonstrated that the early recurrence and poor prognosis of CK19(+) HCC may be due to the expression of CDH17, a gene known to be associated with vascular invasion, tumor metastasis, and advanced tumor stage of HCC. Thus, novel therapeutics by targeting CDH17 may be beneficial for CK19(+) HCC.",
keywords = "Cadherin 17, Cytokeratin 19, Hepatocellular carcinoma, Hepatoma, Keratin 19, Prognosis, Recurrence",
author = "Lee, {Chao Wei} and Sey-En Lin and Tsai, {Hsin I.} and Su, {Po Jung} and Hsieh, {Chia Hsun} and Kuo, {Yung Chia} and Sung, {Chang Mu} and Lin, {Cheng Yu} and Tsai, {Chi Neu} and Yu, {Ming Chin}",
year = "2018",
month = "1",
day = "1",
doi = "10.3892/ol.2017.7320",
language = "English",
volume = "15",
pages = "559--567",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Cadherin 17 is related to recurrence and poor prognosis of cytokeratin 19-positive hepatocellular carcinoma

AU - Lee, Chao Wei

AU - Lin, Sey-En

AU - Tsai, Hsin I.

AU - Su, Po Jung

AU - Hsieh, Chia Hsun

AU - Kuo, Yung Chia

AU - Sung, Chang Mu

AU - Lin, Cheng Yu

AU - Tsai, Chi Neu

AU - Yu, Ming Chin

PY - 2018/1/1

Y1 - 2018/1/1

N2 - A previous study demonstrated that cytokeratin 19 (CK19) expression in hepatocellular carcinoma (HCC) is an indicator of HCC invasiveness, including lymph node metastasis (LNM), tumor infiltration/non‑encapsulation and poor prognosis. The exact mechanism by which CK19 expression results in poor prognosis remains unclear. Through the use of an Affymetrix U133A oligonucleotide microarray [20 patients with hepatitis B virus (HBV)-HCC], it was demonstrated that cadherin 17 (CDH17) significantly correlated with CK19 expression (R2, 0.867; P10% and CDH17 expression were independent prognostic factors for disease free survival (P=0.010 and 0.002, respectively). In vitro studies showed that epidermal growth factor can induce the expression of both CK19 and CDH17, and CDH17 in turn can enhance the expression of CK19 in HCC. In summary, this study demonstrated that the early recurrence and poor prognosis of CK19(+) HCC may be due to the expression of CDH17, a gene known to be associated with vascular invasion, tumor metastasis, and advanced tumor stage of HCC. Thus, novel therapeutics by targeting CDH17 may be beneficial for CK19(+) HCC.

AB - A previous study demonstrated that cytokeratin 19 (CK19) expression in hepatocellular carcinoma (HCC) is an indicator of HCC invasiveness, including lymph node metastasis (LNM), tumor infiltration/non‑encapsulation and poor prognosis. The exact mechanism by which CK19 expression results in poor prognosis remains unclear. Through the use of an Affymetrix U133A oligonucleotide microarray [20 patients with hepatitis B virus (HBV)-HCC], it was demonstrated that cadherin 17 (CDH17) significantly correlated with CK19 expression (R2, 0.867; P10% and CDH17 expression were independent prognostic factors for disease free survival (P=0.010 and 0.002, respectively). In vitro studies showed that epidermal growth factor can induce the expression of both CK19 and CDH17, and CDH17 in turn can enhance the expression of CK19 in HCC. In summary, this study demonstrated that the early recurrence and poor prognosis of CK19(+) HCC may be due to the expression of CDH17, a gene known to be associated with vascular invasion, tumor metastasis, and advanced tumor stage of HCC. Thus, novel therapeutics by targeting CDH17 may be beneficial for CK19(+) HCC.

KW - Cadherin 17

KW - Cytokeratin 19

KW - Hepatocellular carcinoma

KW - Hepatoma

KW - Keratin 19

KW - Prognosis

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=85035318686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035318686&partnerID=8YFLogxK

U2 - 10.3892/ol.2017.7320

DO - 10.3892/ol.2017.7320

M3 - Article

AN - SCOPUS:85035318686

VL - 15

SP - 559

EP - 567

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 1

ER -